Epiodyne

Epiodyne is a pharmaceutical company specializing in the development of opioid medicines with minimal side effects and reduced addiction potential. Operating in the healthcare and pharmaceutical market, Epiodyne serves patients requiring pain relief and treatment for Opioid Use Disorder (OUD). The company has built a comprehensive drug discovery platform that enables selective activation of the mu opioid receptor (MOR), allowing for the creation of small molecule opioids that are precisely calibrated for desired therapeutic effects, ranging from full inhibitors to full agonists. Epiodyne's business model focuses on advancing its lead candidate, partial MOR agonist EPD 2520, through clinical trials to demonstrate its efficacy and safety. Revenue is generated through the development and commercialization of these innovative opioid therapies. The company's approach aims to address critical unmet medical needs by providing safer and more effective pain relief and OUD treatments, thereby contributing to the mitigation of the Opioid Crisis.

Keywords: opioid medicines, minimal side effects, reduced addiction, mu opioid receptor, drug discovery, pain relief, Opioid Use Disorder, clinical trials, pharmaceutical, healthcare.